Letters to the Editor

Interleukin-17-associated inflammation in non-responders and B-cell remodeling after daratumumab in refractory immune thrombocytopenia

Precision Immunotherapy Alliance (PRIMA) and KG Jebsen Centre for B cell Malignancy, Department of Immunology, University of Oslo and Oslo University Hospital, Norway; Institute of Clinical Medicine, University of Oslo, Oslo
Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Hematology-Oncology, Østfold Hospital Trust, Kalnes, Norway; Division of Medicine, Department of Hematology, Haukeland University Hospital, Bergen
Precision Immunotherapy Alliance (PRIMA) and KG Jebsen Centre for B cell Malignancy, Department of Immunology, University of Oslo and Oslo University Hospital, Norway; Institute of Clinical Medicine, University of Oslo, Oslo
Precision Immunotherapy Alliance (PRIMA) and KG Jebsen Centre for B cell Malignancy, Department of Immunology, University of Oslo and Oslo University Hospital, Norway; Institute of Clinical Medicine, University of Oslo, Oslo
Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo
Department of Hematology, Akershus University Hospital, Oslo
Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Hematology, Oslo University Hospital, Oslo
Department of Hematology, Oslo University Hospital, Oslo
Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Hematology-Oncology, Østfold Hospital Trust, Kalnes
Precision Immunotherapy Alliance (PRIMA) and KG Jebsen Centre for B cell Malignancy, Department of Immunology, University of Oslo and Oslo University Hospital, Norway; Institute of Clinical Medicine, University of Oslo, Oslo
Precision Immunotherapy Alliance (PRIMA) and KG Jebsen Centre for B cell Malignancy, Department of Immunology, University of Oslo and Oslo University Hospital, Norway; Institute of Clinical Medicine, University of Oslo, Oslo
Haematologica Early view Sep 3, 2026 https://doi.org/10.3324/haematol.2026.301032